These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32734559)

  • 1. Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
    He L; Yang N; Xu L; Ping F; Li W; Li Y; Zhang H
    Diabetes Ther; 2020 Sep; 11(9):2121-2143. PubMed ID: 32734559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.
    Krisanapan P; Sanpawithayakul K; Pattharanitima P; Thongprayoon C; Miao J; Mao MA; Suppadungsuk S; Tangpanithandee S; Craici IM; Cheungpasitporn W
    Diseases; 2024 Jan; 12(1):. PubMed ID: 38248365
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression.
    Qiu M; Ding LL; Zhang M; Lin JH; Wei XB; Huang H
    Diabetes Ther; 2020 Oct; 11(10):2429-2440. PubMed ID: 32852698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
    Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
    Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M; Maisnam I; Mukhopadhyay S
    Cardiovasc Drugs Ther; 2023 Jan; ():. PubMed ID: 36696050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.
    Cao C; Yang S; Zhou Z
    Endocrine; 2019 Nov; 66(2):157-165. PubMed ID: 31420784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis.
    Lavalle-Cobo A; Masson W; Lobo M; Masson G; Molinero G
    High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):605-612. PubMed ID: 34705249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap.
    Zafeiropoulos S; Pagiantza A; Doundoulakis I; Stalikas N; Farmakis I; Samaras A; Antza C; Giannakoulas G
    Curr Pharm Des; 2021; 27(8):1068-1079. PubMed ID: 33463455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
    Liu Y; Ruan B; Jiang H; Le S; Liu Y; Ao X; Huang Y; Shi X; Xue R; Fu X; Wang S
    Am J Clin Nutr; 2023 Sep; 118(3):614-626. PubMed ID: 37661106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes.
    Guo X; Sang C; Tang R; Jiang C; Li S; Liu N; Long D; Du X; Dong J; Ma C
    Diabetes Obes Metab; 2023 Apr; 25 Suppl 1():53-63. PubMed ID: 36864658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.
    Yuan X; Gao Z; Hao Z; Ma H; Duan K; Yang C
    Medicine (Baltimore); 2023 Oct; 102(43):e35739. PubMed ID: 37904378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical potential of treatment with semaglutide in type 2 diabetes patients.
    Røder ME
    Drugs Context; 2019; 8():212585. PubMed ID: 31844422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.